Cyclic lipodepsipeptides (CLiPs) are a class of secondary metabolites produced by soil-borne bacteria such as Pseudomonas spp. that share a common blueprint, namely: a relative short oligopeptide sequence where the N-terminus is acylated with a fatty acid moiety. The ester bond establishes the macrocyclic nature by involving the C-terminus and a hydroxyl functionality. A great incentive for researching these unique molecules has been their pronounced biological activity profile. Aside from their beneficial traits to their natural ecological niche (e.g bioremediation, plant promoting potential,..) it was found that they offer tremendous potential in the fight against multi-resistant bacteria. Recently, their anticancer properties were demons...
The use of natural products isolated from microorganisms is becoming a promising alternative approac...
In recent years, strains of bacteria with resistance to conventional antibiotics have been emerging ...
Antibiotic resistance is a major public health challenge, and Gram-negative multidrug-resistant bact...
International audienceCyclic lipo(depsi)peptides (CLiPs) from Pseudomonas constitute a class of natu...
Abstract Many Pseudomonas spp. produce cyclic lipodepsipeptides (CLPs), which, besides their role in...
Cyclic lipodepsipeptides or CLiPs from Pseudomonas are secondary metabolites that mediate a wide ran...
The viscosin group covers a series of cyclic lipodepsipeptides (CLPs) produced by Pseudomonas bacter...
Cyclic lipo(depsi)peptides (CLiPs) from Pseudomonas constitute a class of natural products involved ...
The viscosin group covers a series of cyclic lipodepsipeptides (CLPs) produced by Pseudomonas bacter...
J. Pept. Sci. 18, S160-S161.Cyclic lipodepsipeptides (CLPs) are secondary metabolites produced by va...
Cyclic lipodepsipeptides (CLPs) are a diverse group of secondary metabolites produced by various bac...
Cyclic lipodepsipeptides (CLPs) are generally produced by bacteria such as Pseudomonas and Bacillus ...
Cyclic lipodepsipeptides (CLPs) are a class of secondary metabolites typically produced by Pseudomon...
Cyclic lipodepsipeptides (CLPs) are non-ribosomal bacterial peptides, which exhibit antagonistic act...
Pseudomonads produce several lipopeptide biosurfactants that have antimicrobial properties, but also...
The use of natural products isolated from microorganisms is becoming a promising alternative approac...
In recent years, strains of bacteria with resistance to conventional antibiotics have been emerging ...
Antibiotic resistance is a major public health challenge, and Gram-negative multidrug-resistant bact...
International audienceCyclic lipo(depsi)peptides (CLiPs) from Pseudomonas constitute a class of natu...
Abstract Many Pseudomonas spp. produce cyclic lipodepsipeptides (CLPs), which, besides their role in...
Cyclic lipodepsipeptides or CLiPs from Pseudomonas are secondary metabolites that mediate a wide ran...
The viscosin group covers a series of cyclic lipodepsipeptides (CLPs) produced by Pseudomonas bacter...
Cyclic lipo(depsi)peptides (CLiPs) from Pseudomonas constitute a class of natural products involved ...
The viscosin group covers a series of cyclic lipodepsipeptides (CLPs) produced by Pseudomonas bacter...
J. Pept. Sci. 18, S160-S161.Cyclic lipodepsipeptides (CLPs) are secondary metabolites produced by va...
Cyclic lipodepsipeptides (CLPs) are a diverse group of secondary metabolites produced by various bac...
Cyclic lipodepsipeptides (CLPs) are generally produced by bacteria such as Pseudomonas and Bacillus ...
Cyclic lipodepsipeptides (CLPs) are a class of secondary metabolites typically produced by Pseudomon...
Cyclic lipodepsipeptides (CLPs) are non-ribosomal bacterial peptides, which exhibit antagonistic act...
Pseudomonads produce several lipopeptide biosurfactants that have antimicrobial properties, but also...
The use of natural products isolated from microorganisms is becoming a promising alternative approac...
In recent years, strains of bacteria with resistance to conventional antibiotics have been emerging ...
Antibiotic resistance is a major public health challenge, and Gram-negative multidrug-resistant bact...